

2022-2023 INFLUENZA SEASON

Interim results indicate substantial flu vaccine effectiveness (VE)

2022-2023 influenza activity began earlier than normal and was associated with high rates of hospitalization among children.¹

A/H3N2 viruses predominated with co-circulation of A/H1N1, most of which have been well-matched to current season vaccines.¹

Positive interim VE estimates from 2 concurrent studies¹

<u>Interim results from the Marshfield Clinic Health System</u> indicate that influenza vaccination substantially reduced the risk for medically attended influenza among persons age <65 years and for symptomatic influenza in children and adolescents.¹

In children and adults 6 months to 64 years:

- VE was 54% against medically attended, lab-confirmed influenza A
- VE was 60% against influenza A/H3N2

In children and adolescents <18 years:

• **VE was 71%** for preventing symptomatic, lab-confirmed influenza A illness

Full interim estimates

Available in the CDC's Morbidity and Mortality Weekly Report (MMWR)

Click here or scan the code



84% of all vaccinated participants received FLUCELVAX[®] QUADRIVALENT (Influenza Vaccine), the first and only cell-based influenza vaccine for ages 6 months and older in the US.^{1,2}

*Noted as ccIIV4 in the studies.

Study Design: 2022-2023 interim VE was measured in a test-negative, case-control study of patients 6 months-64 years (n=545) and a community cohort study of patients 1-17 years (n=241), during October 23, 2022-February 10, 2023.¹ **Limitations:** small sample sizes from single geographic area and potential for confounding and bias.¹

IMPORTANCE OF FLU VACCINATION¹




Vaccination remains the best way to protect against influenza and its complications Annual vaccination against seasonal influenza is recommended by the CDC for all persons 6+ months for as long as viruses are circulating in the community Increased vaccination coverage is needed to realize the full potential of seasonal influenza vaccines

Please see Important Safety Information for FLUCELVAX QUADRIVALENT and full US Prescribing Information here.

Have you ordered enough flu vaccine for your patients?

Talk to your CSL Seqirus representative about vaccine ordering and planning. You can also visit <u>flu360.com</u> to place or update an order. Together, **we've got flu covered**[®].



FLUCELVAX° QUADRIVALENT (Influenza Vaccine) INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 6 months of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUCELVAX QUADRIVALENT. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.

After vaccination with FLUCELVAX QUADRIVALENT, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response. Vaccination with FLUCELVAX QUADRIVALENT may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (27.9%), erythema (25.8%), induration (17.3%) and ecchymosis (10.7%). The most common systemic adverse reactions were irritability (27.9%), sleepiness (26.9%), diarrhea (17.9%) and change of eating habits (17.4%).

In children 2 through 8 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28.7%), pain (27.9%) and erythema (21.3%), induration (14.9%) and ecchymosis (10.0%). The most common systemic adverse reactions were sleepiness (14.9%), headache (13.8%), fatigue (13.8%), irritability (13.8%) and loss of appetite (10.6%).

In children and adolescents 9 through 17 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were injection site pain (21.7%), erythema (17.2%) and induration (10.5%). The most common systemic adverse reactions were headache (18.1%) and fatigue (17.0%).

In adults 18 through 64 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain (45.4%), erythema (13.4%) and induration (11.6%). The most common systemic adverse reactions were headache (18.7%), fatigue (17.8%) and myalgia (15.4%).

In adults ≥65 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain (21.6%) and erythema (11.9%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or <u>www.vaers.hhs.gov</u>.

Before administration, please see the <u>full US Prescribing</u> <u>Information</u> for FLUCELVAX QUADRIVALENT.

FLUCELVAX $^\circ$ QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

References: 1. McLean HQ, Petrie JG, Hanson KE, et al. Interim estimates of 2022-23 seasonal influenza vaccine effectiveness — Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023;72(8);201-205. doi:10.15585/mmwr.mm7208a1. 2. FLUCELVAX QUADRIVALENT. Package insert. Seqirus Inc.

For US Healthcare Professional Use Only

flu360, FLUCELVAX QUADRIVALENT, and WE'VE GOT FLU COVERED are registered trademarks of Seqirus UK Limited or its affiliates. Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA ©2023 Seqirus USA Inc. March 2023 USA-FLU360-23-0011

